Peptide API Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Peptide API Market: By Category (Biologically Active Peptides, Enzyme Inhibitors, Polypeptides, Oligopeptides, and Others), By Therapeutic Area (Cancer, Cardiovascular, Respiratory, Nervous Systems, Gastrointestinal, and Others), By End User (Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes & Universities, and Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Peptide API market report gives comprehensive outlook on peptide API across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of category (biologically active peptides, enzyme inhibitors, polypeptides, oligopeptides, and others), by therapeutic area (cancer, cardiovascular, respiratory, nervous systems, gastrointestinal, and others), by end user (biopharmaceutical companies, pharmaceutical companies, research institutes & universities, and others) and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global peptide API products. The three most common therapeutic areas where peptide APIs are used are oncology, diabetes, and obesity. Peptides are also in high demand as antibiotics and vaccines for treating cardiovascular, renal, and other diseases. Currently, injection is used to administer more than 80% of authorised peptide medicines. Oral and other forms of delivery are becoming more popular.

Peptide API Market

MARKET SUMMARY
-
x
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR–x%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Peptide API Market Analysis

  • Global peptide API market expanding at significant CAGR over 2021 to 2027 owing to rising prevalence of chronic disorders and rising advancements in technology for the development of new products and drugs
  • Based on category, biologically active peptides segment of peptide API accounted for larger market revenue share in 2018 and projected to gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global market
Market Leaders
  • CordenPharma
  • Hemmo Pharmaceuticals Pvt Ltd.
  • Auspep (Australia)
  • BACHEM
  • BAM Biotech Company
  • CS Bio (California)
  • Almac Group
  • Tapi Teva
  • Novetide
Peptide API Market Analysis

Drivers and Restraints

owing to increase in scientific advancements and rising number of pharmaceutical and biopharmaceutical companies across the globe are expected to propel the growth of the market. Additionally, launch of novel technologies and strategic collaborations between the market players are expected to enhance the sales of the market. However manufacturing peptide API is a complex process that involves sophisticated technology and expert oversight are expected to hamper the growth of the market.


North-America Got Significant Share

Pet Food Market

North America accounted for larger revenue share in global pet food market with a CAGR of XX% and is expected to grow over the forecast years. North America is anticipated to held largest pet food market share and will present numerous growth opportunities to market players during the predicted period. The pet humanization trend and the rising demand for nutritional and premium pet food will considerably influence market growth in this region.US is one of the key markets for pet food in North America. Asia Pacific held significant market share during estimated period owing to increasing demand for premium dog food.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Peptide API Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The Peptide API Market Analysis was valued at x in 2021

 

The Peptide API Market Analysis is poised to grow at a significant CAGR  of x% from 2022 to 2028.

 

  • CordenPharma, Hemmo Pharmaceuticals Pvt Ltd, Auspep (Australia), BACHEM, BAM Biotech Company, CS Bio (California)

North America is dominating the global Peptide API Market Analysis

 


Report

Table Of Content

1. Executive Summary
2. Global Peptide API Market Introduction
2.1. Global Peptide API Market – Taxonomy
2.2. Global Peptide API Market –Definitions
2.2.1. Category
2.2.2. Therapeutic Area
2.2.3. End User
2.2.4. Region
3. Global Peptide API Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Peptide API Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Player’s Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Peptide API Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Peptide API Market Analysis, By Category, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Biologically Active Peptides
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Enzyme Inhibitors
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Polypeptides
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Oligopeptides
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. Global Peptide API Market Analysis, By Therapeutic Area, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Cardiovascular
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Respiratory
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Nervous Systems
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Gastrointestinal
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Peptide API Market Analysis, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Biopharmaceutical Companies
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Pharmaceutical Companies
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Research Institutes & Universities
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Peptide API Market Analysis, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. The Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Peptide API Market – Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Region, 2022 – 2028
9. North America Peptide API Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Category Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Biologically Active Peptides
9.1.2. Enzyme Inhibitors
9.1.3. Polypeptides
9.1.4. Oligopeptides
9.1.5. Others
9.2. Therapeutic Area Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Cancer
9.2.2. Cardiovascular
9.2.3. Respiratory
9.2.4. Nervous Systems
9.2.5. Gastrointestinal
9.2.6. Others
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Biopharmaceutical Companies
9.3.2. Pharmaceutical Companies
9.3.3. Research Institutes & Universities
9.3.4. Others
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.4.1. The U.S.
9.4.2. Canada
9.5. North America Peptide API Market – Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2022 – 2028
9.6. North America Peptide API Market Dynamics – Trends
10. Europe Peptide API Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Category Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Biologically Active Peptides
10.1.2. Enzyme Inhibitors
10.1.3. Polypeptides
10.1.4. Oligopeptides
10.1.5. Others
10.2. Therapeutic Area Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Cancer
10.2.2. Cardiovascular
10.2.3. Respiratory
10.2.4. Nervous Systems
10.2.5. Gastrointestinal
10.2.6. Others
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Biopharmaceutical Companies
10.3.2. Pharmaceutical Companies
10.3.3. Research Institutes & Universities
10.3.4. Others
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. The UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Peptide API Market – Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2022 – 2028
10.6. Europe Peptide API Market Dynamics – Trends
11. Asia-Pacific Peptide API Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Category Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Biologically Active Peptides
11.1.2. Enzyme Inhibitors
11.1.3. Polypeptides
11.1.4. Oligopeptides
11.1.5. Others
11.2. Therapeutic Area Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Cancer
11.2.2. Cardiovascular
11.2.3. Respiratory
11.2.4. Nervous Systems
11.2.5. Gastrointestinal
11.2.6. Others
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Biopharmaceutical Companies
11.3.2. Pharmaceutical Companies
11.3.3. Research Institutes & Universities
11.3.4. Others
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Peptide API Market – Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2022 – 2028
11.6. Asia-Pacific Peptide API Market Dynamics – Trends
12. Latin America Peptide API Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Category Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Biologically Active Peptides
12.1.2. Enzyme Inhibitors
12.1.3. Polypeptides
12.1.4. Oligopeptides
12.1.5. Others
12.2. Therapeutic Area Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Cancer
12.2.2. Cardiovascular
12.2.3. Respiratory
12.2.4. Nervous Systems
12.2.5. Gastrointestinal
12.2.6. Others
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Biopharmaceutical Companies
12.3.2. Pharmaceutical Companies
12.3.3. Research Institutes & Universities
12.3.4. Others
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Mexico
12.4.4. Rest of Latin America
12.5. Latin America Peptide API Market – Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2022 – 2028
12.6. Latin America Peptide API Market Dynamics – Trends
13. The Middle East and Africa Peptide API Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. Category Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Biologically Active Peptides
13.1.2. Enzyme Inhibitors
13.1.3. Polypeptides
13.1.4. Oligopeptides
13.1.5. Others
13.2. Therapeutic Area Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Cancer
13.2.2. Cardiovascular
13.2.3. Respiratory
13.2.4. Nervous Systems
13.2.5. Gastrointestinal
13.2.6. Others
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Biopharmaceutical Companies
13.3.2. Pharmaceutical Companies
13.3.3. Research Institutes & Universities
13.3.4. Others
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of MEA
13.5. MEA Peptide API Market – Opportunity Analysis Index, By Category, Therapeutic Area, End User, and Country, 2022 – 2028
13.6. MEA Peptide API Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, CategoryOfferings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. CordenPharma
14.2.2. Hemmo Pharmaceuticals Pvt Ltd.
14.2.3. Auspep (Australia)
14.2.4. BACHEM
14.2.5. BAM Biotech Company
14.2.6. CS Bio (California)
14.2.7. Almac Group
14.2.8. Tapi Teva
14.2.9. Novetide
14.2.10. Lyotex Sciences
14.2.11. Aspen Oss
14.2.12. Peptide Institute I
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • CordenPharma
  • Hemmo Pharmaceuticals Pvt Ltd.
  • Auspep (Australia)
  • BACHEM
  • BAM Biotech Company
  • CS Bio (California)
  • Almac Group
  • Tapi Teva
  • Novetide
  • Lyotex Sciences
  • Aspen Oss
  • Peptide Institute Inc.

Description

Peptide API market report gives comprehensive outlook on peptide API across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of category (biologically active peptides, enzyme inhibitors, polypeptides, oligopeptides, and others), by therapeutic area (cancer, cardiovascular, respiratory, nervous systems, gastrointestinal, and others), by end user (biopharmaceutical companies, pharmaceutical companies, research institutes & universities, and others) and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global peptide API products. The three most common therapeutic areas where peptide APIs are used are oncology, diabetes, and obesity. Peptides are also in high demand as antibiotics and vaccines for treating cardiovascular, renal, and other diseases. Currently, injection is used to administer more than 80% of authorised peptide medicines. Oral and other forms of delivery are becoming more popular.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX